Other NIH Programs for Translational Neuroscience

Funding for High Throughput Screening

Preclinical Screening Platform for Pain (PSPP)

  • Support: Within the NIH HEAL Initiative, NINDS created the Preclinical Screening Platform for Pain (PSPP) to identify and profile non-addictive therapeutics (small molecules, biologics, devices, or natural products) for acute and chronic pain.
  • Participating Institutes: FIC, NCI, NCATS, NCCIH, NEI, NHLBI, NIA, NIAAA, NIBIB, NIDCR, NIDDK, NIDA, NINDS
  • To apply: contact Program Director, Smriti Iyengar, smriti.iyengar@nih.gov

IGNITE: Assay Development and Neurotherapeutic Agent Identification

  • Support: 3-year R61/R33 support assay development and neurotherapeutic agent identification
  • Participating Institutes: NINDS, NCCIH
  • To apply: PAR-21-124

Funding for Medicinal Chemistry (Hit-to-Lead)

Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes

  • Support: 3-year R01s to improve probes for in vivo proof-of-concept studies
  • Participating Institutes: NIMHNEINIANIDA
  • To apply: PAR-21-029

Funding for Preclinical Proof-of-Concept

Drug Discovery for Nervous System Disorders

  • Support: Up to 5 years (R01) or 2 years (R21) of funding to support the discovery of novel compounds for the prevention and treatment of nervous system disorders.
  • Participating Institutes: NIMHNIANIAAANIDA
  • To apply: PAR-19-147 (R01), PAR-19-146 (R21)

IGNITE: Neurotherapeutic Agent Characterization and In vivo Efficacy Studies

  • Support: 3-year R61/R33 support Neurotherapeutic Agent Characterization and In vivo Efficacy Studies
  • Participating Institute: NINDS
  • To apply: PAR-21-122

Funding for Translational Model Development

IGNITE: Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

  • Support: 3- year R61/R33 to support Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery
  • Participating Institute: NINDS
  • To apply: PAR-21-123

Funding for Preclinical/Clinical Development

National Cooperative Drug Discovery/Development Groups (NCDDG)

  • Support: Up to 5 years of funding for multidisciplinary teams, Public Private Partnerships
  • Participating InstitutesNIMHNIAAA
  • To apply: PAR-22-143 (U01), PAR-22-144 (U19)

Regulatory Affairs Assistance for Medications Development

  • Support: Provides consultation and advice on regulatory requirements
  • Participating Institute: NIDA
  • To apply: Contact Marta DeSantis, Acting Branch Chief

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (STTR)

  • Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
  • Participating Institute: NIAAA
  • To apply: PAR-22-103 (UT1/UT2 - Clinical Trial Optional)

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (SBIR)

  • Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
  • Participating Institute: NIAAA
  • To apply: PAR-22-102 (U43/U44 - Clinical Trial Optional)

Strategic Alliances for Medications Development to Treat Substance-Use Disorders

  • Support: Up to 3 years of funding, includes discovery, development, and clinical trials. $3M per year with expectation of matching funds
  • Participating Institute: NIDA
  • To apply: PAR-19-318 (R01)

Grand Opportunities in Medications Development for Substance-Use Disorders

  • Support: Up to 3 years of funding, milestone-driven, up to $5M per year
  • Participating Institute: NIDA
  • To apply: PAR-19-327 (U01)

Alzheimer's Drug-Development Program

  • Support: Up to 5 years of funding, milestone-driven, up to $1M per year
  • Participating Institute: NIA
  • To apply: PAR-22-047 (U01)

Services

Services for Pharmacology

Epilepsy Therapy Screening Program (ETSP)

  • Support: Screens compounds in animal seizure models
  • To apply: Contact Brian Klein, Ph.D.

Addiction Treatment Discovery Program (ATDP)

  • Support: Screens compounds in animal models of addiction
  • To apply: Contact David White, Ph.D., (301) 443-8889

NIMH Psychoactive Drug Screening Program (PDSP)

  • Support: Screens novel psychoactive compounds for pharmacological and functional activity at cloned human or rodent CNS receptors, channels, and transporters.
  • To apply: Contact Jamie Driscoll, (301) 443-5288

Services for Toxicology

Bridging Interventional Development Gaps (BrIDGs)

NIMH Toxicological Evaluation of Novel Ligands Program

  • Support: Provides toxicology, safety, in vitro ADME, and pharmacokinetic assessment of promising, target-selective compounds for use as imaging ligands and novel psychoactive drugs.
  • To apply: Contact Jamie Driscoll, (301) 443-5288

NIDA Toxicology Program

  • Support: Provides IND-directed toxicology services for substance abuse indications.
  • To apply: Contact Nathan M. Appel, Ph.D., (301) 443-8475

Services for Chemistry

Bridging Interventional Development Gaps (BrIDGs)

NIDA Drug Supply Program

  • Support: Provides chemicals and research probes that are either unavailable, difficult to obtain, or very expensive to buy to researchers, including marijuana plant materials, cannabinoids, opioids, stimulants, sedatives, hypnotics, standardized research E-Cigarettes and nicotine research c, etc. Also provides analytical services for the analysis of researchers’ experimental samples.
  • To apply: Contact: Richard Kline, Ph.D., (301) 443-5280

NIMH Chemical Synthesis and Drug Supply Program

  • Support: Synthesizes and distributes novel research chemicals, psychoactive drugs, and compounds unavailable from commercial sources. Also supports radiosynthesis, medicinal chemistry, and GMP synthesis for clinical studies.
  • To apply: Contact Jamie Driscoll, (301) 443-5288

NIDA Chemistry and Pharmaceutics Branch

  • Support: Medicinal chemistry, analytical chemistry, metabolism, pharmacokinetics and pharmacodynamics, pharmacogenetics and pharmaceutics/formulation development aimed at the design, evaluation and development of medications for the treatment of drug addiction
  • To apply: Contact Rik Klein, (301)-827-5243, rkline@nida.nih.gov

BPN Staff